urologic cancers: renal cell carcinoma (RCC)

Studies

ID Name Stage Status
MARC-2 Everolimus in patients with metastatic RCC after VEGF-targeted therapy failure metastatic 2nd line
 active
113387 Pazopanib for locally advanced RCC following nephrectomy (PROTECT) various active
FLIPPER metastatic
 active
BERAT metastatic
 active
MGN1601-CU1 metastatic 3rd line
 active
NO21884 RAD001 + R1507 metastatic 2nd line
 closed
AV-951-09-301 metastatic
 closed
B1131004 metastatic 2nd line
 closed
  Compassionate use für Temsirolimus metastatic
 closed
NN028-1642 Sunitinib + Interleukin-21 metastatic
 closed
A6181109 Sunitinib vs. placebo for righ risk renal cell cancer (S-TRAC) adjuvant
 closed
NCC 001 Sorafenib bei älteren Patienten mit metastasiertem Nierenzellkarzinon metastatic
 closed
CZOL446EDE15 Zoledronat bei Knochenmetastasen metastatic
 closed
CRAD001C2240 RAD001 nach Progress unter Sorafenib oder Sunitinib metastatic 2nd line
 closed
A6181034 First-Line-Therapie mit SU011248 metastatic
 closed
A6181037 Behandlung mit SU011248 metastatic 2nd line
 closed
KM-Kinetik Studie KM-Kinetik unter Therapie mit Sunitinib various closed
  Podozytenstudie bei Patienten mit RCC und Therapie mit Sunitinib various closed
CRAD001L2401 RAD001 Expanded Access Program (REACT) metastatic 2nd line
 closed
CRAD001L2201 metastatic
 closed
  Gerinnungsanalysen unter TKI various closed
A4061046 metastatic
 closed
CTKI258A2302 Dovitinib (TKI258) metastatic 3rd line
 closed
CESAR C-II-006 metastatic
 closed
MGN1601-CT1 ASET - Phase 1/2 study of a tumor vaccine with MGN1601 metastatic 3rd line
 closed
VEG108844 metastatic
 closed
CTKI258A2107 TKI258 for renal cell carcinoma metastatic
 closed
RCC SWITCH Sorafenib vs. sunitinib -> sunitinib vs. sorafenib metastatic
 closed
IMA901-301 IMA901 in patients receiving sunitinib for advanced/metastatic RCC metastatic
 closed
ROVER metastatic 2nd line
metastatic 3rd line
 closed